You just read:

Eiger Announces First Patient Dosed in Phase 2 Multiple Ascending Dose Study of Subcutaneous Exendin (9-39) in Patients with Hypoglycemia Post-Gastric Bypass Surgery

News provided by

Eiger BioPharmaceuticals, Inc.

May 10, 2016, 08:00 ET